Finerenone: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CHUIKYO (Japan), G-BA (Germany) and HIRA (South Korea), among others, recommended or restricted finerenone, while AOTMIT (Poland) did not recommend it.
Where finerenone met resistance it was usually narrowed rather than refused: 6 of 16 decisive outcomes were recommendations with restrictions, against 5 outright refusals.
The record spans 4.5 years, opening at AWMSG (Wales) on 23 Mar 2022 and running to 28 Sep 2026.
No assessment is on file from HAS (France) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
The file is active: 13 of 21 records date from 2023 or later.
7 distinct indication wordings are recorded for finerenone by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
3 of these 21 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess finerenone, on 23 Mar 2022; CIPM (Spain) did not open a file until 23 Nov 2023 — a moderate spread of 1.7 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 3 years in total.
Restriction is doing real work here: 6 of 16 decisive outcomes narrowed finerenone to a subgroup rather than accepting or refusing it outright, at G-BA (Germany), NICE (England) and TLV (Sweden) among others.
7 of the 11 agencies here assessed finerenone more than once, TLV (Sweden) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
11 of the 18 agencies in this archive hold a record for finerenone.
The full ledger for finerenone reads 6 restricted, 5 not recommended, 5 recommended and 2 appraised, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NICE (England) | 5 Aug 2026 | NICE TA1182 | published appraisal | source |
| AWMSG (Wales) | 5 Aug 2026 | Treatment of symptomatic chronic heart failure with left ventricular ejection fraction (LVEF) for more than or equal to … | excluded, NICE appraised | source |
| PBAC (Australia) | 2026 | Heart failure | Not Recommended | source |
| CIPM (Spain) | 13 Dec 2023 | Indicación terapéutica autorizada: Kerendia está indicado en adultos para el tratamiento de la enfermedad renal crónica … | financed by the SNS · art. 92 a, c | source |
| HIRA (South Korea) | 12 Oct 2023 | 제 2 형 당뇨가 있는 만성 신장병 | reimbursement appropriate | source |
16 further decisions for finerenone, across 10 agencies, are not shown here. They include the most recent record on file, 28 Sep 2026 from TLV (Sweden); its outcome is in the subscriber dataset. They link to 14 further source documents.
Related molecules
- empagliflozin — divergent outcome (restricted vs recommended) on a shared indication
- capivasertib — also decided by TLV in 2026Q3
- pirtobrutinib — also decided by TLV in 2026Q3
- dupilumab — also decided by TLV in 2026Q3
- pertuzumab / trastuzumab — also decided by TLV in 2026Q3
- lazertinib — also decided by TLV in 2026Q3
Coverage: 21 decisions for finerenone from 11 agencies, 2022 to 2026. Data to 7 Sep 2026. ATC class C09 — Renin-angiotensin system. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.